Copyright
©The Author(s) 2019.
World J Hepatol. Dec 27, 2019; 11(12): 761-772
Published online Dec 27, 2019. doi: 10.4254/wjh.v11.i12.761
Published online Dec 27, 2019. doi: 10.4254/wjh.v11.i12.761
Table 3 Magnetic resonance imaging proton density fat fraction and biochemistry for all subjects and stratified by modulator (lumacaftor/ivacaftor) status
Reference range | All subjects, n = 20 | CFTR modulator, n = 9 | No CFTR modulator, n = 11 | P value | |
PDFF (%) | < 5% | 3.0 (0.0-21.0) | 2.0 (0.0-6.4) | 4.1 (2.7-21.0) | 0.002 |
HbA1C (%) | < 5.8% | 5.8 (5.2-8.2) | 6.3 (5.3-8.2) | 5.7 (5.2-7.4) | 0.21 |
Alk Phos (U/L) | 1 | 110 (44-310) | 66 (44-178) | 155 (103-310) | 0.01 |
Alk Phos (SD) | -2.0-2.0 | 1.2 (-1.5-4.8) | -0.3 (-1.5-4.7) | 1.8 (-0.6-4.8) | 0.07 |
Total bilirubin (µmol/L)2 | 0-20.5 | 6.8 (3.4-20.5) | 5.1 (3.4-6.8) | 8.6 (3.4-20.5) | 0.003 |
AST (U/L) | 9-39 | 23 (11-45) | 20 (11-42) | 27 (11-45) | 0.39 |
ALT (U/L) | 10-52 | 22 (10-58) | 18 (10-45) | 29 (12-58) | 0.19 |
GGT (U/L) | 5-64 | 14 (9-29) | 12 (9-24) | 19 (10-29) | 0.07 |
Triglyceride (mmol/L)3 | < 1.7 | 1.02 (0.36-2.55) | 0.9 (0.64-2.55) | 1.25 (0.36-2.35) | 0.79 |
- Citation: Kutney K, Donnola SB, Flask CA, Gubitosi-Klug R, O’Riordan M, McBennett K, Sferra TJ, Kaminski B. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. World J Hepatol 2019; 11(12): 761-772
- URL: https://www.wjgnet.com/1948-5182/full/v11/i12/761.htm
- DOI: https://dx.doi.org/10.4254/wjh.v11.i12.761